Related Experiment Videos
PLGA-PEG nano-delivery system for epigenetic therapy.
Asia Naz1, Yi Cui2, Christopher J Collins3
1Bindley Bioscience Center and Purdue Center for Cancer Research, Department of Agricultural and Biological Engineering, Purdue University, West Lafayette, IN 47907, USA; Department of Pharmaceutical Chemistry, University of Karachi, Karachi 75270, Pakistan.
Summary
This study presents a novel nano-vector for delivering Azacitidine (AZA) to solid tumors, enhancing anti-cancer effects by reactivating key genes. The nanocarrier shows improved cellular uptake and drug release for epigenetic therapy.
Area of Science:
- Nanotechnology
- Epigenetics
- Cancer Therapy
Background:
- Efficient delivery of cytidine analogues like Azacitidine (AZA) to solid tumors is a major hurdle in epigenetic cancer therapies.
- Current methods face challenges in stabilizing AZA under physiological conditions and ensuring effective cellular uptake.
Purpose of the Study:
- To develop a novel di-block nano-vector for enhanced delivery of Azacitidine (AZA) in epigenetic therapies.
- To evaluate the anti-proliferative efficacy and intracellular behavior of the AZA-loaded nano-vector in breast cancer models.
Main Methods:
- Development of a di-block nano-vector using poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG).
- In vitro and in vivo studies in breast cancer models to assess anti-proliferative effects.
- Single-molecule fluorescence tools were used to analyze intracellular behavior, drug release, and cellular uptake mechanisms.
Main Results:
- The AZA-loaded nano-vector demonstrated superior anti-proliferative effects compared to free AZA in vitro and in vivo.
- The nano-vector effectively reactivated p21 and BRCA1, leading to restricted cell proliferation.
- Nano-micelles showed enhanced accumulation in cancer cells, independent of nucleoside transporters, with pH-dependent release and resistance to efflux.
Conclusions:
- The developed PLGA-PEG nano-vector offers an effective strategy for delivering DNA demethylating agents like AZA.
- This nanoscale delivery system provides tunable properties and a potentially cost-effective option for pharmaceutical applications in cancer therapy.